UCLA scientists have developed a new method to engineer more powerful immune cells that can potentially be used for "off-the-shelf" cell therapy to treat challenging cancers.
Nov 8, 2023
0
84
Chimeric antigen receptor (CAR) T cell therapy, which uses engineered T cells to treat certain types of cancers, has often been a challenging approach to treating solid tumors. CAR T cells need to recognize a specific target ...
Sep 2, 2021
0
59
Researchers in the Cockrell School of Engineering at The University of Texas at Austin have discovered a correlation between aging and the effectiveness of T-cells, a type of immune cell programmed to fight or kill a threat. ...
Jun 1, 2016
1
154
A CAR T-cell therapy known as axicabtagene ciloleucel (axi-cel) drove cancer cells to undetectable levels in nearly 80% of patients with advanced non-Hodgkin lymphoma (NHL) in a phase 2 clinical trial, Dana-Farber Cancer ...
Dec 5, 2020
0
187
In a study out this week in Science Translational Medicine, an international team led by researchers at Vanderbilt University Medical Center sheds new light on the cause of pulmonary fibrosis and demonstrates a way to impede ...
Oct 5, 2018
0
41
New adoptive T cell therapies—in which T cells, the immune system's natural hunters patrolling the body for foreign adversaries, are retrieved from cancer-riddled patients, super-charged and amplified outside the body, ...
Feb 10, 2023
0
59
Scientists at St. Jude Children's Research Hospital are improving chimeric antigen receptor (CAR) T-cell therapy. Their new simplified approach selected for an advantageous T-cell type and showed promise in the lab against ...
Aug 5, 2022
0
39
Blood cancer patients, especially when they relapse, have a poor prognosis, and generally do not survive very long. The last five years have seen success in treating these patients with Chimeric Antigen Receptor (CAR) T-cells—a ...
Feb 24, 2023
0
50
Adoptive T cell therapies, including chimeric antigen receptor (CAR) T cell therapy, which use genetically engineered killer immune T cells, are emerging forms of immunotherapy that redirect the immune system to target cancer.
May 19, 2020
0
80
A patient with relapsed T cell leukaemia has been given base-edited T-cells in a world-first use of a base-edited cell therapy, in a 'bench-to-bedside' collaboration between UCL and Great Ormond Street Hospital for Children ...
Dec 11, 2022
0
60
